Glucocorticoid-Related Adverse Events in ANCA-Associated Vasculitis
<b>Introduction:</b> Glucocorticoid (GC)-sparing treatment strategies, such as the C5a receptor antagonist avacopan, could potentially replace the need for long-term GC therapy in ANCA-associated vasculitis (AAV). Therefore, an assessment of GC-related morbidity is required to provide justification...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2026-03-01
|
| Col·lecció: | Kidney and Dialysis |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/2673-8236/6/1/20 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|